Compare Ford Motor Company (F) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Merck & Co., Inc. — how do they compare? Ford Motor Company trades at $12.17 (market cap $48.85B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.2× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and Merck & Co., Inc. for 98 Days on average.
| F | MRK | |
|---|---|---|
Market Cap | $48.85B | $351.28B |
Volume | 57,748,965 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $156.43 |
52-Week Low | $11.21 | $82.49 |
Typical Hold Time | 105 Days | 98 Days |
Enterprise Value | $180.81B | $398.04B |
Dividend Yield | 4.9% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.25, up 1.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported disappointing Q3 2026 sales with a 6.6% decline due to model phase-outs and supplier issues, though hybrid vehicle adoption shows promise. Financially, Ford maintains strong operating cash flow of $21.28 billion but faces profitability challenges with negative net income margins and declining revenue growth trends.
Ford presents a value opportunity with attractive valuation multiples (P/E 11.21, P/S 0.26) and analyst consensus target of $15.90 offering 30% upside potential. However, investors face significant risks from ongoing sales declines, competitive pressures from Asian automakers, and operational challenges including recent vehicle recalls and production disruptions. The company's transition to hybrids and commercial vehicle strength provides potential catalysts amid current headwinds.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
